Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
6,477.16
(
-1.74%
)
US TECH 100
22,824.00
(
-0.56%
)
Dow Jones
45,960.11
(
-1.01%
)
Brent Oil
104.48
(
3.78%
)
Bitcoin
66,722.00
(
-3.00%
)
News Focus
News Focus
Post# of 257295
Next 10
Public Reply Private Reply New Post
Keep Last Read
Replies (2) Keep Next 10 Report Keyboard Shortcuts
Replies (2) Next 10 Prev Next

jq1234

Send PM Follow Ignore
Followers 69
Posts 4516
Boards Moderated 0
Alias Born 12/13/2009

jq1234

Re: DewDiligence post# 177580

Monday, 05/05/2014 5:19:12 PM

Monday, May 05, 2014 5:19:12 PM

Post# of 257295
Yes, GSK/THRX are still developing triple combo of ICS/LABA/LAMA. In addition, they are also to develop next generation product Bifunctional Muscarinic Antagonist-Beta2 Agonist (MABA), with both muscarinic antagonist (MA) and beta2 agonist (BA) activities in one single molecule.

AZN new acquisition Pearl Therapeutics is developing ICS/LABA/LAMA triple combo as well.
Public Reply Private Reply New Post
Keep Last Read
Replies (2) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (2) Next 10 Prev Next

Discover What Traders Are Watching

Explore small cap ideas before they hit the headlines.

Join Today